Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 8

PMID 33680911

Citations 21

Authors

Bin Zhang

Xilei Wang

Ping Cheng

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses (OVs) are potential antitumor agents with unique therapeutic mechanisms. They possess the ability of direct oncolysis and the induction of antitumor immunity. OV can be genetically engineered to potentiate antitumor efficacy by remodeling the tumor immune microenvironment. The present mini review mainly describes the effect of OVs on remodeling of the tumor immune microenvironment and explores the mechanism of regulation of the host immune system and the promotion of the immune cells to destroy carcinoma cells by OVs. Furthermore, this article focuses on the utilization of OVs as vectors for the delivery of immunomodulatory cytokines or antibodies.

Citing Articles

Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.

Beder N, Mirbahari S, Belkhelfa M, Mahdizadeh H, Totonchi M Explor Target Antitumor Ther. 2025; 6:1002294.

PMID: 40061139 PMC: 11886384. DOI: 10.37349/etat.2025.1002294.

Improving systemic delivery of oncolytic virus by cellular carriers.

Peng Z, Kalim M, Lu Y Cancer Biol Med. 2025; 21(12).

PMID: 39831754 PMC: 11745088. DOI: 10.20892/j.issn.2095-3941.2024.0390.

Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.

Raimondi V, Vescovini R, Dessena M, Donofrio G, Storti P, Giuliani N Front Immunol. 2024; 15:1483806.

PMID: 39539548 PMC: 11557349. DOI: 10.3389/fimmu.2024.1483806.

Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer.

Ferdous K, Tesfay M, Cios A, Shelton R, Hartupee C, Urbaniak A Biomedicines. 2024; 12(7).

PMID: 39062169 PMC: 11275208. DOI: 10.3390/biomedicines12071596.

Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future.

Yarahmadi A, Zare M, Aghayari M, Afkhami H, Jafari G Cell Commun Signal. 2024; 22(1):239.

PMID: 38654309 PMC: 11040964. DOI: 10.1186/s12964-024-01622-w.

References

Dempe S, Lavie M, Struyf S, Bhat R, Verbeke H, Paschek S . Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother. 2012; 61(11):2113-23. PMC: 11028688. DOI: 10.1007/s00262-012-1279-4. View

Gujar S, Dielschneider R, Clements D, Helson E, Shmulevitz M, Marcato P . Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther. 2013; 21(2):338-47. PMC: 3594021. DOI: 10.1038/mt.2012.228. View

Donnelly O, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K . Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2011; 20(1):7-15. PMC: 3378495. DOI: 10.1038/gt.2011.205. View

Zamarin D, Holmgaard R, Subudhi S, Park J, Mansour M, Palese P . Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014; 6(226):226ra32. PMC: 4106918. DOI: 10.1126/scitranslmed.3008095. View

Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom W, Hay J . Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther. 2001; 12(10):1323-32. DOI: 10.1089/104303401750270977. View

Steidl C, Lee T, Shah S, Farinha P, Han G, Nayar T . Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010; 362(10):875-85. PMC: 2897174. DOI: 10.1056/NEJMoa0905680. View

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

El-Shemi A, Ashshi A, Na Y, Li Y, Basalamah M, Al-Allaf F . Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res. 2016; 35:74. PMC: 4859966. DOI: 10.1186/s13046-016-0353-8. View

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

10.

Altomonte J, Marozin S, Schmid R, Ebert O . Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. 2009; 18(2):275-84. PMC: 2839313. DOI: 10.1038/mt.2009.231. View

11.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

12.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

13.

Crespo J, Sun H, Welling T, Tian Z, Zou W . T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013; 25(2):214-21. PMC: 3636159. DOI: 10.1016/j.coi.2012.12.003. View

14.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

15.

Kim M, Osborne N, Zeng W, Donaghy H, McKinnon K, Jackson D . Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes. J Immunol. 2012; 188(9):4158-70. DOI: 10.4049/jimmunol.1103450. View

16.

Kennedy B, Murphy J, Clements D, Konda P, Holay N, Kim Y . Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus. Cancer Res. 2019; 79(15):3824-3836. DOI: 10.1158/0008-5472.CAN-18-2414. View

17.

Wongthida P, Diaz R, Galivo F, Kottke T, Thompson J, Melcher A . VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther. 2010; 19(1):150-8. PMC: 3017452. DOI: 10.1038/mt.2010.225. View

18.

Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab J . Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother. 2018; 67(6):999-1009. PMC: 8697037. DOI: 10.1007/s00262-018-2131-2. View

19.

Lee H, Park I, Song I, Shin S, Kim J, Yu J . Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol. 2015; 69(5):422-30. DOI: 10.1136/jclinpath-2015-203089. View

20.

Cooper M, Elliott J, Keyel P, Yang L, Carrero J, Yokoyama W . Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009; 106(6):1915-9. PMC: 2644138. DOI: 10.1073/pnas.0813192106. View